Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

By Sebba Anthony I.   Bonnick Sydney Lou   Kagan Risa   Thompson Desmond E.   Skalky Carol S.   Chen Erluo   de Papp Anne E.    

Current Medical Research and Opinion, Vol. 20, Iss. 12, 2004-12 ,pp. : 2031-2041

Informa Healthcare

Access to resources Recommend Favorite

Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 468-473

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epoetin β Once-Weekly Therapy in Anemic Patients with Solid Tumors and Non-Myeloid Hematological Malignancies Receiving Chemotherapy

By  

Oncology, Vol. 74, Iss. 1-2, 2008-06 ,pp. : 112-118

Karger

Access to resources Recommend Favorite

Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget’s disease

By Hooper M.   Faustino A.   Reid I.   Hosking D.   Gilchrist N.   Selby P.   Wu M.   Salzmann G.   West J.   Leung A.  

Osteoporosis International, Vol. 20, Iss. 1, 2009-01 ,pp. : 141-150

Springer Publishing Company

Access to resources Recommend Favorite

Treatment satisfaction in people with type 2 diabetes mellitus treated with once‐weekly dulaglutide: data from the AWARD‐1 and AWARD‐3 clinical trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 9, 2015-09 ,pp. : 896-903

John Wiley & Sons Inc

Access to resources Recommend Favorite